Design Therapeutics (DSGN) shares were up 3% in recent Wednesday trading after Leerink upgraded its rating on the biopharmaceutical firm's stock to outperform from market perform and adjusted its price target to $14 from $7.
Trading volume stood at about 384,000 shares against a daily average of over 280,000.
Price: 9.21, Change: +0.27, Percent Change: +3.02